Characteristics of severe asthma in adolescents treated by dupilumab in the PEDIASTHMA study

• Published in: Revue française d'allergologie (2009) 2024-04, Vol.64, p.104046, Article 104046
• Main Authors: Deschildre, A., Abou Taam, R., Giovannini Chami, L., Marguet, C., Just, J., Daridon, C., Da Silva, C.
• Format: Article
• Language: English
• ISSN: 1877-0320; 1877-0320
• DOI: 10.1016/j.reval.2024.104046

PEDIASTHMA is a multicenter, observational, retrospective and prospective real-life study evaluating the use of dupilumab in adolescents ≥ 12 years of age with severe uncontrolled asthma. To describe characteristics of patients enrolled in PEDIASTHMA with severe asthma. This analysis presents the phenotypic characteristics of severe asthma at the initiation of dupilumab in 50 adolescents enrolled in 15 centers. Results are expressed as median [IQ25–75] or n (%). Thirty-three (66%) were males, with a median age of 14.9 [13.1–15.9] years. Patients were 8.1 [4.7–12.7] years old when they had a diagnosis of severe asthma. 27 (54.0%) had been previously treated with biotherapy, including 7 (25.9%) with ≥ 1 biotherapy. At baseline, the number of severe exacerbations in the previous year was 2.0 (1.0–5.0), pre-BD FEV1 81.0% [67.0–94.0], FEV1/FVC 80.0% [71.0–91.0], blood eosinophilia 0.38 (0.16–0–0.53) G/L, FeNO 35.8 [11.0–66.9] ppb. 33 (66%) of the patients were sensitized to ≥ 1 aeroallergen, 15 (30.0%) had food allergy, 32 (64.0%) allergic rhinitis, 28 (56.0%) atopic dermatitis, and 1 (2.0%) eosinophilic esophagitis. The expected features of severe adolescent asthma were found in this cohort. However, one in two adolescents had severe lung function impairment and one in two was prescribed dupilumab after another biotherapy. In relation to published randomized trials(ref), the follow-up of this cohort will allow us to monitor the real-world response of dupilumab on asthma control and lung function.